ITEMS IN AFP WITH KEYWORD:

Colorectal Cancer

Feb 15, 2017 Issue
Aspirin for the Prevention of Cardiovascular Disease and Colorectal Cancer: New Recommendations from the USPSTF [Editorials]

In April 2016, the U.S. Preventive Services Task Force (USPSTF) updated its recommendation on the use of aspirin to prevent cardiovascular disease (CVD). Because emerging evidence suggested that aspirin may also be useful for the prevention of cancer, for the first time, the USPSTF developed a recom...


Feb 15, 2017 Issue
Screening for Colorectal Cancer: Recommendation Statement [U.S. Preventive Services Task Force]

The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.


Oct 15, 2016 Issue
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer [Putting Prevention into Practice]

S.L. is a 55-year-old man who presents to your office for a routine refill of his antihypertension medication. He also takes a statin and an antidepressant. Although he smokes, his blood pressure and cholesterol are well controlled. His history and physical examination are unremarkable.


Oct 15, 2016 Issue
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendation Statement [U.S. Preventive Services Task Force]

The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, ...


Jan 15, 2015 Issue
Colorectal Cancer Screening and Surveillance [Article]

Colon cancer screening should begin at 50 years of age in average-risk persons. Find out the recommendations for patients with risk factors, and surveillance guidelines based on initial screening results.


Jan 15, 2015 Issue
Screening and Surveillance for Colorectal Cancer: Avoiding the Pitfalls of Overscreening [Editorials]

Although much has been written about the need to encourage colonoscopy in underscreened populations, overscreening for colorectal cancer is now recognized as a problem that can lead to harm.


Sep 1, 2014 Issue
Accuracy of Fecal DNA and Fecal Immunochemical Test for Colorectal Cancer Detection [POEMs]

Fecal DNA testing is more sensitive but less specific than fecal immunochemical testing (FIT), and as a result, has a higher false-positive rate. It is also more expensive than other noninvasive alternatives such as FIT. We do not know which test will be better at reducing mortality.


Aug 15, 2014 Issue
Immunochemical FOBTs Moderately Sensitive and Highly Specific for Colorectal Cancer [POEMs]

Immunochemical FOBTs, such as OC-Micro, OC-Sensor, or OC-Light, are moderately sensitive (73% to 89%) and highly specific (92% to 95%) for identifying colorectal cancer. In comparison, Hemoccult Sensa has a lower sensitivity (64% to 80%) and specificity (87% to 90%). Immunochemical FOBTs also have the advantage of requiring only one sample.


May 1, 2014 Issue
No Increased Survival Benefit to Intensive Follow-Up After Colorectal Cancer Surgery [POEMs]

Compared with minimal follow-up after surgery for colorectal cancer, intensive follow-up with regular computed tomography (CT), carcinoembryonic antigen (CEA) testing, or both results in more patients undergoing repeat surgery but no reduction in overall mortality or disease-specific mortality.


Oct 15, 2013 Issue
Colorectal Neoplasia Yield Similar for FIT Every One, Two, or Three Years [POEMs]

There appears to be no advantage to obtaining FIT more often than every three years.


Pages: 1 2 3 Next


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now